| Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update |
- Announced robust preclinical data supporting the unique three-pronged mechanism of action of micvotabart pelidotin (MICVO, formerly PYX-201), driving anti-tumor activity via direct tumor killing, bystander effect and immunogenic cell death |
globenewswire.com |
2025-05-15 11:00:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Participate in Two Upcoming Investor Conferences |
BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation ADC therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in fireside chats and be available for one-on-one meetings with investors at the following two upcoming investor conferences. |
globenewswire.com |
2025-05-14 11:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC |
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders |
globenewswire.com |
2025-04-25 17:17:00 |
Czytaj oryginał (ang.) |
| 5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms |
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio. |
zacks.com |
2025-04-23 14:35:35 |
Czytaj oryginał (ang.) |
| Top Cancer Stocks to Buy to Boost Your Portfolio's Health |
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics. |
zacks.com |
2025-04-16 14:46:10 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum |
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event. |
globenewswire.com |
2025-04-02 11:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 |
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response |
globenewswire.com |
2025-03-25 18:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update |
- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Received Fast Track Designation from the U.S. Food and Drug Administration for MICVO for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy - Initiated monotherapy expansion cohorts of MICVO for 2L and 3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy with preliminary data expected in 2H25 and 2/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy with preliminary data expected 1H26 - Initiated MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in 1/2L+ R/M HNSCC patients as part of a recently announced Clinical Trial Collaboration Agreement with Merck (known as MSD outside of the US and Canada) with preliminary data expected in 2H25 - Streamlined organization and implemented operational initiatives to focus resources on the execution of the MICVO clinical program, including workforce reduction of approximately 20% - Expected cash runway into 2H26 BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2024, and provided a business update. “We are committed to the development of a novel therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma who will progress following platinum-based therapies and prior PD-(L)1 therapy, and those that progress after current and emerging EGFRi therapies,” said Lara S. |
globenewswire.com |
2025-03-18 09:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference |
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D. |
globenewswire.com |
2025-03-03 09:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer |
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody |
globenewswire.com |
2025-02-26 09:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial |
- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck's KEYTRUDA® (pembrolizumab) in multiple solid tumors |
globenewswire.com |
2025-02-04 09:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 |
- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors - Current cash runway expected to fund development into 2H 2026 BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types. |
globenewswire.com |
2024-12-19 18:08:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead |
Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types. |
seekingalpha.com |
2024-12-07 03:30:22 |
Czytaj oryginał (ang.) |
| Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns |
On Wednesday, Pyxis Oncology, Inc. PYXS released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors. |
benzinga.com |
2024-11-21 11:18:34 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data |
— PYX-201 achieved a confirmed 50% ORR by RECIST 1.1 including one Complete Response and 100% Disease Control Rate in six heavily pretreated HNSCC patients, supporting differentiated mono and front-line combo therapy expansion trials to begin dosing 1Q25 |
globenewswire.com |
2024-11-20 18:05:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside |
Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company's technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability, and tolerability. |
benzinga.com |
2024-11-08 15:30:09 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Pyxis Oncology, Inc. (NASDAQ:PYXS) |
NEW YORK , Sept. 25, 2024 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Pyxis Oncology, Inc. (NASDAQ:PYXS) concerning possible breaches of fiduciary duty. |
prnewswire.com |
2024-09-25 23:15:00 |
Czytaj oryginał (ang.) |
| Moment Of Truth Approaches For Pyxis Oncology |
Pyxis Oncology is an antibody and antibody-drug conjugate developer with initial results from two clinical trials ahead in 2024. Data from a phase 1 study of PYX-201, an ADC targeting extra domain B of fibronectin, in multiple tumor types, are expected in fall 2024. Data from a phase 1 study of PYX-106, an anti-Siglec-15 antibody, in multiple tumor types, are expected by year-end 2024. |
seekingalpha.com |
2024-09-13 11:08:46 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Participate in Two Upcoming Investor Conferences |
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in fireside chats and members of management will participate in one-on-one meetings at the following two upcoming investor conferences: |
globenewswire.com |
2024-08-29 11:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024 |
- Preliminary data from the Phase 1 trial of PYX-201 remains on track to be announced in the fall of 2024 - Preliminary data from the Phase 1 trial of PYX-106 is expected to be reported by year-end 2024 - Expected cash runway into 2H 2026 BOSTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. The Company ended the second quarter of 2024 with $157.2 million in cash, cash equivalents, restricted cash and short-term investments, which is expected to provide cash runway into the second half of 2026 and enable the Company to fund the next phase of PYX-201 clinical development, which the Company plans to announce in the fall of 2024. |
globenewswire.com |
2024-08-14 20:05:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Participate in the BTIG Virtual Biotechnology Conference |
BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, and members of management will participate in one-on-one meetings at the BTIG Virtual Biotechnology Conference being held August 5-6, 2024. |
globenewswire.com |
2024-07-29 12:00:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 89,530 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 111,913 shares of Pyxis Oncology's common stock to five newly hired employees. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of June 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-06-28 20:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Expands Board of Directors with Appointment of Michael A. Metzger |
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effective June 10, 2024. Mr. Metzger has over 25 years of experience in the biopharmaceutical sector, currently serving as Chief Executive Officer and as a member of the Board of Directors of Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) since 2015. |
globenewswire.com |
2024-06-10 11:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference |
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Thursday, June 6, 2024 at 9:00 AM Eastern Time at the Jefferies Global Healthcare Conference in New York City, where members of management will also host investor one-on-one meetings. |
globenewswire.com |
2024-05-30 11:30:00 |
Czytaj oryginał (ang.) |
| Q2 2024 EPS Estimates for Pyxis Oncology, Inc. (NASDAQ:PYXS) Decreased by Analyst |
Pyxis Oncology, Inc. (NASDAQ:PYXS – Free Report) – Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for shares of Pyxis Oncology in a research note issued on Thursday, May 16th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.27) per share for the quarter, down from their previous estimate of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Pyxis Oncology’s Q3 2024 earnings at ($0.15) EPS, Q4 2024 earnings at ($0.16) EPS, FY2024 earnings at ($0.63) EPS, Q1 2025 earnings at ($0.41) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.49) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.42) EPS and FY2028 earnings at ($0.70) EPS. A number of other research analysts have also issued reports on PYXS. Royal Bank of Canada restated an “outperform” rating and set a $7.00 price target on shares of Pyxis Oncology in a research note on Friday, March 22nd. SVB Leerink initiated coverage on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. They set an “outperform” rating and a $12.00 price target on the stock. BTIG Research initiated coverage on shares of Pyxis Oncology in a research note on Friday, February 9th. They set a “buy” rating and a $8.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Pyxis Oncology in a research note on Tuesday, January 23rd. Finally, Jefferies Financial Group restated a “buy” rating and set a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $8.80. Read Our Latest Research Report on PYXS Pyxis Oncology Stock Down 0.5 % NASDAQ:PYXS opened at $4.15 on Monday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The firm has a 50 day moving average of $4.68 and a 200 day moving average of $3.54. The stock has a market capitalization of $244.39 million, a price-to-earnings ratio of -3.05 and a beta of 1.45. Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last posted its earnings results on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.19. The firm had revenue of $16.15 million for the quarter, compared to analysts’ expectations of $4.25 million. Institutional Trading of Pyxis Oncology Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Decheng Capital Management III Cayman LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $650,000. abrdn plc acquired a new stake in Pyxis Oncology during the fourth quarter valued at $1,275,000. Acadian Asset Management LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Commonwealth Equity Services LLC acquired a new stake in Pyxis Oncology during the third quarter valued at $26,000. Finally, Schulhoff & Co. Inc. acquired a new stake in Pyxis Oncology during the third quarter valued at $44,000. Institutional investors and hedge funds own 39.09% of the company’s stock. About Pyxis Oncology (Get Free Report) Pyxis Oncology, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. See Also Five stocks we like better than Pyxis Oncology What Does a Stock Split Mean? MarketBeat Week in Review – 5/13 – 5/17 What does consumer price index measure? Take-Two Interactive Software Offers 2nd Chance for Investors 3 Fintech Stocks With Good 2021 Prospects Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 05:06:37 |
Czytaj oryginał (ang.) |
| Pyxis Oncology, Inc. (PYXS) Reports Q1 Loss, Tops Revenue Estimates |
Pyxis Oncology, Inc. (PYXS) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.54 per share a year ago. |
zacks.com |
2024-05-14 13:41:06 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Provides Corporate Update and Reports Financial Results for First Quarter 2024 |
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway into 2H 2026 BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. PYX-201, a first-in-concept tumor stroma targeting antibody-drug conjugate (ADC) against the stromal Extradomain-B Fibronectin (EDB+FN) target, has dosed 42 patients in 8 cohorts since initiating the Phase 1 trial in March 2023 with continued enthusiasm for this agent by global investigators. |
globenewswire.com |
2024-05-14 11:30:00 |
Czytaj oryginał (ang.) |
| Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference |
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings. |
globenewswire.com |
2024-05-09 11:30:00 |
Czytaj oryginał (ang.) |
| Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect? |
The average of price targets set by Wall Street analysts indicates a potential upside of 61.3% in Pyxis Oncology (PYXS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2024-04-12 14:56:12 |
Czytaj oryginał (ang.) |
| Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology's common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology's common stock to a newly hired employee. The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan with a grant date of March 28, 2024, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-03-28 18:30:00 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks to Buy on the Dip: March 2024 |
One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30. |
investorplace.com |
2024-03-27 15:07:58 |
Czytaj oryginał (ang.) |